Summary
Immunotherapy with interleukin 2 (IL-2) is not an effective anti-cancer treatment in the majority of patients with renal cell carcinoma (RCC), suggesting that the activation of cytotoxic T cells or NK cells may be impaired in vivo in these patients. The production of immunosuppressive factors by RCC was investigated. Using immunohistochemistry, IL-10 was detectable in 10 of 21 tumour samples tested. IL-10 was undetectable in the supernatant of cell lines derived from these RCCs. However, these cell lines or their conditioned medium (RCC CM), but not normal renal epithelial cells adjacent to the RCC or breast carcinoma cell lines, were found to induce IL-10, as well as prostaglandin E2(PGE2) and tumour necrosis factor (TNF)α production by autologous or allogeneic peripheral blood mononuclear cells (PBMCs) and monocytes. IL-10 production induced by RCC CM was found to be dependent on TNF-α and PGE2since an anti-TNF-α antibody (Ab) inhibited 40–70% of IL-10 production by monocytes, and the combination of anti-TNF-α Ab and indomethacin, an inhibitor of PGE2 production, inhibited 80–94% of RCC CM-induced IL-10 production by monocytes. The RCC CM of the five cell lines tested were found to induce a down-regulation of the expression of HLA-DR and CD86, as well as a strong inhibition of mannose receptor-dependent endocytosis by monocytes. The blockade of HLA-DR and CD86 expression was partially abrogated by indomethacin and anti-IL-10 Ab respectively, and completely abrogated by an anti-TNF-α Ab. The inhibition of mannose receptor-dependent endocytosis was partially abrogated by an anti-IL-10 Ab and completely abrogated by an anti-TNF-α Ab. These esults indicate that RCCs induce IL-10, PGE2and TNF-α production by monocytes, which down-regulate the expression of cell-surface molecules involved in antigen presentation as well as their endocytic capacity.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Abrams, J. S., Roncarolo, M. G., Yssel, H., Andersson, U., Gleich, G. J. & Silver, J. E. (1992). Strategies of anti-cytokine monoclonal antibody development: immunoassay of IL-10 and IL-5 in clinical samples. Immunol Rev 127: 5–24.
Alleva, D. G., Askew, D., Burger, C. J. & Elgert, K. D. (1993). Tumor-induced macrophage Tumor Necrosis Factor-α production suppresses autoreactive T cells. Immunobiology 188: 430–435.
Bachwich, P. R., Chensue, S. W., Larrick, J. W. & Kunkel, S. L. (1986). Tumor necrosis factor α stimulates interleukin-1 and prostaglandin-E2 production in resting macrophages. Biochem Biophys Res Commun 136: 94–101.
Bain, C., Puisieux, I., Merrouche, Y., Duc, A., Colombo, M. P. & Favrot, M. C. (1996). B7.1 gene transduction of human renal-cell-carcinoma cell lines restores the proliferative response and cytotoxic function of allogeneic T cells. Int J Cancer 67: 769–776.
Benjamin, D., Knoblock, T. J. & Dayton, M. A. (1992). Human B cell interleukin-10: B cell lines derived from patients with acquired immunodeficiency syndrome and Burkitt’s lymphoma constitutively secrete large quantities of interleukin-10. Blood 80: 1289–1298.
Blay, J. Y., Burdin, N., Rousset, F., Lenoir, G., Biron, P., Philip, T., Banchereau, J. & Favrot, M. C. (1993). Serum interleukin-10 in non-Hodgkin’s lymphoma: a prognostic factor. Blood 82: 2169–2174.
Capsoni, F., Minonzio, F., Ongari, A. M., Carbonelli, V., Galli, A. & Zanussi, C. (1995). IL-10 up-regulates human monocyte phagocytosis in the presence of IL-4 and IFNγ. J Leukoc Biol 58: 351–358.
Cohen, P. J., Lotze, M. T., Roberts, J. R., Rozenberg, S. & Jaffé, E. S. (1987). The immunopathology of sequential tumor biopsies in patients treated with IL2: correlation of response with T cell infiltration and HLA-DR expression. Am J Pathol 129: 208–216.
Combaret, V., Wang, Q., Favrot, M. C., Thiesse, P., Philip, I., Bouffet, E., Bailly, C., Bouvier, R., Chauvin, F., Zucker, J. M., Bernard, J. L., Lenoir, G. & Philip, T. (1989). Clinical value of N-myc oncogene amplification in 52 patients with neuroblastoma included in recent therapeutic protocols. Eur J Clin Oncol 24: 1607–1612.
De Waal Malefyt, R., Abrams, J., Bennett, B., Figdor, C. G. & De Vries, J. E. (1991). Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 174: 1209–1220.
De Waal Malefyt, R., Yssel, H. & De Vries, J. E. (1993). Direct effect of IL-10 on subsets of human CD4+T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation. J Immunol 150: 4754–4765.
Emilie, D., Touitou, R., Raphael, N., Peuchmaur, N., Devergnee, O., Coumharas, D. R. J., Crevon, N. C., Edelman, L., Jouab, I. & Galanaud, P. (1992). In vivo production of interleukin-10 by malignant cells in AIDS lymphoma. Eur J Immunol 22: 2937–2942.
Filgueira, L., Zuber, M., Merlo, A., Caetano, V., Schultz, E., Harder, F., Spagnoli, G. C. & Heberer, M. (1993). Cytokine gene transcription in renal cell carcinoma. Br J Surg 80: 1322–1325.
Fiorentino, D. F., Zlotnik, A., Vieira, P., Mosmann, T. R., Howard, M., Moore, K. W. & O’Garra, A. (1991). IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 146: 3444–3451.
Gastl, G. A., Abrams, J. S., Nanus, D. M., Oosterkamp, R., Silver, J., Liu, F., Chen, M., Albino, A. P. & Bander, N. H. (1993). Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression. Int J Cancer 55: 96–101.
Groux, H., O’Garra, A., Bigler, M., Rouleau, M., Antonenko, S., De Vries, J. E. & Roncarolo, M. G. (1997). A CD4+T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389: 737–742.
Hashimoto, S., Yanada, M., Motoyoshi, K. & Akagawa, K. S. (1997). Enhancement of macrophage colony stimulating factor induced growth and differentiation of human monocytes by IL-10. Blood 89: 315–321.
Howard, M. & O’Garra, A. (1992). Biological properties of interleukin 10. Immunol Today 12: 198–201.
Huang, M., Sharma, S., Mao, J. T. & Dubinet, S. M. (1996). Non small lung cancer-derived soluble mediators and prostaglandin E2enhance peripheral blood lymphocyte IL-10 transcription and protein production. J Immunol 157: 5512–5520.
Kambayashi, T., Alexander, R., Fong, M. & Strassmann, G. (1995). Potential involvement of IL-10 in suppressing tumor-associated macrophages. Colon 26 derived PGE-2 inhibits TNFα elease via a mechanism involving IL-10. J Immunol 154: 3383–3390.
Lehmmann, V., Benninghoff, B. & Droge, W. (1988). Tumor necrosis factor α induced activation of peritoneal macrophages is regulated by Prostaglandin-E2 and cAMP. J Immunol 141: 587–591.
Mauerer, M. J., Martin, D. M., Castelli, C., Elder, E., Leder, G., Storkus, W. J. & Lotze, M. T. (1995). Host immune response in renal cell cancer: interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes. Cancer Immunol Immunother 41: 111–121.
Nakagomi, H., Pisa, P., Pisa, E. K., Yamamoto, Y., Halapi, E., Backlin, K., Juhlin, C. & Kiessling, R. (1995). Lack of interleukin-2 (IL-2) expression and selective expression of IL-10 mRNA in human renal cell carcinoma. Int J Cancer 63: 366–371.
Négrier, S., Escudier, B., Lasset, C., Savary, J., Chevreau, C., Ravaud, A., Peny, J. & Mousseau, M. (1996). The FNCLCC CRECY trial: interleukin 2 (IL2) + interferon (IFN)-α is the optimal treatment to induce responses in metastatic renal cell carcinoma (MRCC). Proc Am Soc Clin Oncol 15: 248
Oosterwijk, E., Ruiter, D. J., Hoedemaeker, P. J., Pauwels, E. K. J., Jonas, U., Zwartendijk, J. & Warnaar, S. O. (1986). Monoclonal antibody G-250 recognizes a determinant present in renal cell carcinoma and absent from normal kidney. Int J Cancer 38: 489–494.
Pisa, P., Halapi, E., Pisa, E. K., Gerdin, E., Hising, C., Bucht, A. & Kiessling, R. (1992). Selective expression of interleukin-10, interferonγ and granulocyte–macrophage colony stimulating factor in ovarian cancer biopsies. Proc Natl Acad Sci 89: 7708–7712.
Rosenberg, S. A., White, D. E., Lotze, M. T., Yang, J. C., Linehan, W. M., Seipp, C., Calabro, S., Karp, S. E., Sherry, R. M., Steinberg, S. & White, D. E. (1989). Combination therapy with interleukin-2 and α interferon for the treatment of patients with advanced cancer. J Clin Oncol 7: 1863–1874.
Rubin, J. T., Elwood, L. J., Rosenberg, S. A. & Lotze, M. T. (1989). Immunohistochemical correlates of response to recombinant Interleukin-2-based immunotherapy in humans. Cancer Res 49: 7086–7092.
Sallusto, F. & Lanzavecchia, A. (1994). Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage olony stimulating factor plus interleukin 4 and down regulated by tumor necrosis factor α. J Exp Med 179: 1109–1118.
Sallusto, F., Cella, M., Danieli, C. & Lanzavecchia, A. (1995). Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: down regulation by cytokines and bacterial products. J Exp Med 182: 389–400.
Taga, K., Mostowski, H. & Tosato, G. (1993). Human interleukin 10 can directly inhibit T cell growth. Blood 81: 2964–2971.
Voorzanger, N., Touitou, R., Delecluse, H. J., Rousset, F., Joab, I., Favrot, M. C. & Blay, J. Y. (1996). IL-10 and IL-6 are produced in vivo by non Hodgkin’s lymphoma cells and act as cooperative growth factors. Cancer Res 56: 5499–5505.
Wang, Q., Redovan, C., Tubbs, R., Olencki, T., Klein, E., Kudoh, S., Finke, J. & Bukowski, R. M. (1995). Selective cytokine gene expression in renal cell carcinoma tumor cells and tumor infiltrating lymphocytes. Int J Cancer 61: 780–785.
Wanidworanum, C. & Strober, W. (1993). Predominant role of tumor necrosis factor-α in human monocyte IL-10 synthesis. J Immunol 151: 6853–6861.
Watts, C. (1997). Capture and processing of exogenous antigens for presentation on MHC molecules. Annu Rev Immunol 15: 821–850.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Ménétrier-Caux, C., Bain, C., Favrot, M. et al. Renal cell carcinoma induces interleukin 10 and prostaglandin E2 production by monocytes. Br J Cancer 79, 119–130 (1999). https://doi.org/10.1038/sj.bjc.6690021
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.bjc.6690021
Keywords
This article is cited by
-
Interleukin 10-expressing B cells inhibit tumor-infiltrating T cell function and correlate with T cell Tim-3 expression in renal cell carcinoma
Tumor Biology (2016)
-
Tumor microenvironment is multifaceted
Cancer and Metastasis Reviews (2011)
-
CD40L induces multidrug resistance to apoptosis in breast carcinoma and lymphoma cells through caspase independent and dependent pathways
BMC Cancer (2006)
-
Comparative study of the endotoxemia and endotoxin tolerance on the production of th cytokines and macrophage interleukin-6: Differential regulation of indomethacin
Archives of Pharmacal Research (2002)
-
Allogeneic stem-cell transplantation in renal-cell carcinoma
Current Oncology Reports (2001)
